This is a StreetInsider.com Premium Only Page

Regulus Therapeutics (RGLS) –

Apr 10, 2024 10:06 AM Form SC 13G/A Regulus Therapeutics Filed by: FMR LLC

Apr 9, 2024 04:56 PM Form S-3 Regulus Therapeutics

Mar 25, 2024 04:19 PM Form SC 13G Regulus Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 22, 2024 04:03 PM Form SC 13G Regulus Therapeutics Filed by: Deep Track Capital, LP

Mar 21, 2024 04:30 PM Form 10-K Regulus Therapeutics For: Dec 31

Mar 21, 2024 04:19 PM Form 8-K Regulus Therapeutics For: Mar 21

Mar 21, 2024 04:05 PM Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Mar 20, 2024 04:30 PM Form SC 13G Regulus Therapeutics Filed by: Vivo Opportunity Fund Holdings, L.P.

Mar 19, 2024 06:54 AM Regulus Therapeutics (RGLS) PT Lowered to $11 at Canaccord Genuity

Mar 18, 2024 09:14 PM Form SC 13D/A Regulus Therapeutics Filed by: Growth Equity Opportunities V, LLC

Mar 18, 2024 06:13 AM Leerink Partners Starts Regulus Therapeutics (RGLS) at Outperform

Mar 15, 2024 04:23 PM Form 4 Regulus Therapeutics For: Mar 14 Filed by: PAPADOPOULOS STELIOS

Mar 14, 2024 04:57 PM Form 8-K Regulus Therapeutics For: Mar 11

Mar 13, 2024 07:51 AM Regulus Therapeutics (RGLS) PT Raised to $3 at Wells Fargo

Mar 12, 2024 04:47 PM After-hours movers: Coinbase and Rackspace decline, and more

Mar 12, 2024 06:33 AM Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement

Mar 12, 2024 06:32 AM Regulus Therapeutics (RGLS) Reports Positive Topline Data from the Second Cohort in Phase 1b Trial of RGLS8429

Mar 12, 2024 06:32 AM Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Mar 12, 2024 06:30 AM Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant

Feb 14, 2024 02:54 PM Form SC 13G Regulus Therapeutics Filed by: DAFNA Capital Management LLC

Feb 9, 2024 09:51 AM Form SC 13G/A Regulus Therapeutics Filed by: FMR LLC

Feb 6, 2024 11:06 AM Form SC 13G/A Regulus Therapeutics Filed by: VICTORY CAPITAL MANAGEMENT INC

Jan 18, 2024 08:25 PM Form 4 Regulus Therapeutics For: Jan 18 Filed by: CALSADA CRISPINA

Jan 18, 2024 08:24 PM Form 4 Regulus Therapeutics For: Jan 18 Filed by: Aker Christopher Ray

Jan 18, 2024 08:23 PM Form 4 Regulus Therapeutics For: Jan 18 Filed by: Hagan Joseph P

Jan 18, 2024 10:25 AM Form SC 13G/A Regulus Therapeutics Filed by: FEDERATED HERMES, INC.

Jan 17, 2024 05:19 PM Form 4 Regulus Therapeutics For: Jan 12 Filed by: Klassen Preston

Jan 17, 2024 05:16 PM Form 4 Regulus Therapeutics For: Jan 12 Filed by: Hagan Joseph P

Jan 17, 2024 05:09 PM Form 4 Regulus Therapeutics For: Jan 12 Filed by: CALSADA CRISPINA

Jan 17, 2024 05:05 PM Form 4 Regulus Therapeutics For: Jan 12 Filed by: Aker Christopher Ray

Jan 12, 2024 04:12 PM Form S-8 Regulus Therapeutics

Jan 10, 2024 06:03 AM Form EFFECT Regulus Therapeutics

Jan 2, 2024 04:05 PM Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polyc

Dec 27, 2023 04:18 PM Regulus Therapeutics (RGLS) Files $150M Mixed Shelf

Dec 27, 2023 04:16 PM Form S-3 Regulus Therapeutics

Nov 22, 2023 08:00 AM Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 9, 2023 04:41 PM Form 10-Q Regulus Therapeutics For: Sep 30

Nov 9, 2023 04:37 PM Regulus Therapeutics (RGLS) Reports In-Line Q3 EPS

Nov 9, 2023 04:18 PM Form 8-K Regulus Therapeutics For: Nov 09

Nov 9, 2023 04:05 PM Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Nov 2, 2023 08:00 AM Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Diseas

Oct 19, 2023 08:00 AM Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 21, 2023 08:04 AM Regulus Therapeutics (RGLS) PT Raised to $12 at Canaccord Genuity

Sep 20, 2023 07:02 AM Regulus Therapeutics (RGLS) Announces Positive Topline Data from First Cohort of Patients in its Phase 1b MAD Clinical Trial of RGLS8429 for Treatment of ADPKD

Sep 20, 2023 07:00 AM Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant

Sep 13, 2023 08:00 AM Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Poly

Sep 5, 2023 08:00 AM Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Aug 23, 2023 08:00 AM Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Aug 14, 2023 04:40 PM Form 4 Regulus Therapeutics For: Aug 10 Filed by: Collier Kathryn J

Aug 14, 2023 04:37 PM Form 4 Regulus Therapeutics For: Aug 10 Filed by: Witz Pascale